TAVI: current and future perspectives for adjunctive pharmacological therapy

Chairperson: Stephan WINDECKER


To understand TAVI: patient population characteristics, approved devices and expected clinical outcomes
To evaluate current and future antithrombotic therapy options around TAVI
To understand future perspectives and upcoming studies


Session objectives

S. Windecker

TAVI: a paradigm shift in the treatment of symptomatic, severe aortic stenosis - Past, present and future

M.B. Leon

TAVI-2015: stroke and bleeding risk update

A.S. Petronio

Solved and unsolved issues of antithrombotic therapy after TAVI

J. Rodés Cabau

Future perspective and upcoming studies

P. Vranckx

Session evaluation and key learnings

G. Dangas


More from Bayer Healthcare Pharmaceuticals

Visit website